ArticleInternational urology and nephrology2022
Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.
Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Upper Urinary Tract Urothelial Carcinoma Diagnosis Effect on Life Expectancy Relative to Population-Based Controls: A Retrospective Analysis.Urologia internationalis · 2026Article
- Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.Journal of racial and ethnic health disparities · 2025Article
- The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.Journal of racial and ethnic health disparities · 2025Article
- Differences in life expectancy of adrenocortical carcinoma patients vs. age‑ and sex-matched population controls.International urology and nephrology · 2025Article
- Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.BJU international · 2024Article
- The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.BJUI compass · 2024Review
- Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older.Frontiers in oncology · 2024Article
- Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls.International urology and nephrology · 2023Article
- Smoking, ethnicity and bladder cancer - implications for public health and clinical practice.Nature reviews. Urology · 2023Article
- Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy.Arab journal of urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeto compare observed overall survival vs age-adjusted lifetable (LT) derived life expectancy (LE) in metastatic urothelial bladder cancer (MBCa) patients according to race/ethnicity.
methodsWe identified Caucasian, African American, Hispanic/Latino and Asian metastatic urothelial bladder cancer patients from 2004 to 2011 within the Surveillance, Epidemiology and End Results database. Social Security Administration tables were used to compute 5 year LE. LT-derived LE was compared to observed overall survival OS. Additionally, we relied on Poisson regression plots to display cancer-specific mortality (CSM) relative to other-cause mortality (OCM) for each race/ethnicity.
resultsOverall, 2286 MBCa patients were identified. Of those, 1800 (79%) were Caucasian vs 212 (9.3%) African American vs 189 (8.3%) Hispanic/Latino vs 85 (3.7%) Asians. The median age at diagnosis was 71 years for Asians vs 70 for Caucasians vs 67 for Hispanic/Latinos vs 67 for African Americans. African Americans showed the biggest difference between observed OS and LT-predicted LE at five years (- 83.8%), followed by Hispanic/Latinos (- 81%), Caucasians (- 77%) and Asian patients (- 69%). In Poisson regression plots, Hispanic/Latinos displayed the highest cancer-specific mortality rate (88%), while African/Americans showed the highest other cause mortality rate (12%). Conversely, Asian patients displayed the lowest CSM rate (83%) and second lowest OCM rate (7%).
conclusionsAfrican Americans showed the least favorable survival profile in MBCa, despite being youngest at diagnosis. Contrarily, Asians displayed the best survival profile in MBCa, despite being oldest at diagnosis.
Indexed as
Identifiers
35508792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.